Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. - Wikidata - wikimedia - TriplyDB

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

http://www.wikidata.org/entity/Q43185360

about

Agalsidase alfa: a review of its use in the management of Fabry disease Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.Enzyme replacement therapy for Fabry disease: some answers but more questions Update on role of agalsidase alfa in management of Fabry disease.Carboxyl-terminal truncations alter the activity of the human α-galactosidase A Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.Agalsidase benefits renal histology in young patients with Fabry disease.An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.Fabry disease: clinical and genotypic aspects of three cases in first degree relatives.Fabry disease: a review of current management strategies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Safety of agalsidase alfa in patients with Fabry disease under 7 years.Enzyme replacement in neuronal storage disorders in the pediatric population.Fabry disease in children: agalsidase-beta enzyme replacement therapy.Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.Therapeutic goals in the treatment of Fabry disease.Agalsidase treatment for Fabry disease: uses and rivalries.Fabry disease

P2860

Q28274194-7FD519C9-3B70-441E-BF20-AD80B7E07C1D Q33776219-2FCB413F-173A-4721-8F37-210CC17B6067 Q34659532-E975B5BE-C08F-44AD-B67C-D778E95EE329 Q34703815-2F603957-4814-4E3F-9C87-069D3A3F53BF Q34883178-D7574228-47BC-43D8-92F5-54BD23F47400 Q35125851-D3ECE50A-6DD3-4111-A6A8-75E7CCB135C5 Q35247511-38490D86-1BFB-4024-83A1-A9AC9ACDDD40 Q35848678-D17E2EF7-0FA9-472E-846C-1C3EDE1DCFCF Q36509288-0EF527AA-FA72-4486-98C8-8FC5FABFCDBC Q36951447-D3E17D97-FE1D-4C66-9F4D-84D1D473B686 Q37329223-F72A0F96-426C-4B84-B4BE-A8691DCFA2A3 Q37352268-F0627376-F15B-4A1B-A202-D6EBA2D80E49 Q37609874-C08A66AD-4B45-4734-8A99-CA16F824128A Q37775790-F7B4BDDB-A9C0-493A-BDBF-EFF49A46BB79 Q37801828-C0510EBF-9E77-47FF-96F8-1603132B5DD0 Q37813149-ABD23CB6-CA61-49E9-8E9C-8ACE5907F171 Q43948150-0BC42520-4353-4062-A317-B4CB534E3AC3 Q44093757-ED5BEDF9-923D-4CB4-B6D3-84AC5F7799AA Q46881710-2E220DA3-1E9D-48C4-A341-2BF3698526F3 Q50436079-0477603D-A453-4BD5-A3F0-AF009158C0E2 Q54059373-37E19D39-306D-4250-B1BC-56384626460A Q56905945-54952A7E-CD35-4D7D-B146-6C7614EC10DD

P2860

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

http://www.wikidata.org/entity/Q43185360

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@en

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@nl

type

label

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@en

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@nl

prefLabel

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@en

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@nl

P1433

Q43185360-8A5C8C87-B7B9-46B3-B933-A342AEB99C58

P1476

Q43185360-18E6B916-DB11-4D25-91F4-B82E5FFC295A

P2093

Q43185360-22BCB364-91AF-4ECA-B973-30AB35A7BE29

Q43185360-23401CB8-AB65-44A2-8239-50DFE70B565D

Q43185360-26A7B0C9-6504-438B-891B-CBB509BE2ED5

Q43185360-520A5D3B-0E33-4E8E-A398-7E81D51B3A48

Q43185360-6ADDE4E3-8A5B-492A-8A20-60C0082A60CA

Q43185360-7E56DBA0-26B7-4BBE-A944-79C40046E1F5

Q43185360-E735F6B8-2E93-4704-87C9-CFCAA25FB038

Q43185360-F0FF0F9A-9D27-4110-9A50-63F85B32917C

Q43185360-FE5B490B-5495-4BD8-A209-835AC1CF94B6

P304

Q43185360-E326B7B7-F3C3-4749-8F25-FAC96E19A169

P31

Q43185360-6212B117-BCBB-4930-AE5D-4FC07292E83F

P356

Q43185360-F5D08118-E4DA-4D44-AE14-FFFAFEB531CD

P407

Q43185360-EEA575AF-501C-4F7E-B906-E165A1EEC7C1

P433

Q43185360-F4B8441B-6CE0-4261-8CDA-4A064D4D7A0B

P478

Q43185360-D910EA6C-E9C6-48CE-9514-E1D6EC75A680

P50

Q43185360-7087D82A-7E52-46D1-83BC-54064F36BC9F

P577

Q43185360-FADE774C-C1F1-48FB-B072-757F981BFAB7

P698

Q43185360-181A9FBA-2260-4F9C-AC69-7C7E0CFEBCE4

P356

J.JPEDS.2009.11.007

P1433

The Journal of Pediatrics

P1476

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

@en

P2093

Christoph Kampmann

http://www.w3.org/2001/XMLSchema#string

Gregory M Pastores

http://www.w3.org/2001/XMLSchema#string

Joe T R Clarke

http://www.w3.org/2001/XMLSchema#string

Karen Johnson

http://www.w3.org/2001/XMLSchema#string

Raphael Schiffmann

http://www.w3.org/2001/XMLSchema#string

Rick A Martin

http://www.w3.org/2001/XMLSchema#string

Tyler Reimschisel

http://www.w3.org/2001/XMLSchema#string

Victoria Castaneda

http://www.w3.org/2001/XMLSchema#string

Y Howard Lien

http://www.w3.org/2001/XMLSchema#string

P304

832-7, 837.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPEDS.2009.11.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20097359

http://www.w3.org/2001/XMLSchema#string